GEMMAIR. Grup d’Estudi en Malalties Metabòliques Associades a la Insulin-Resistència

MALALTIES METABÒLIQUES I NUTRICIÓ
OBJECTIUS

GEMMAIR té una llarga trajectòria en l’estudi de la fisiopatologia de l’obesitat i les malalties associades. Actualment, el grup centra principalment la seva recerca en l’estudi de l’hepatopatia grassa no alcohòlica i les seves comorbiditats, com són l’obesitat, la diabetis mellitus de tipus 2 i la síndrome metabòlica, amb la finalitat de definir nous mecanismes moleculars implicats en la malaltia, i trobar possibles biomarcadors i potencials dianes terapèutiques.

RESPONSABLES
  • Teresa Auguet Quintillà

  • PRESENTACIÓ:
  • LÍNIES:
  • MEMBRES DEL GRUP:
  • PROJECTES:
  • TRANSFERÈNCIA:
  • PUBLICACIONS:
  • CONTACTE:

El Grup d’Estudi en Malalties Metabòliques Associades a la Insulin-Resistència (GEMMAIR) és un grup de recerca clínica i bàsica format per un equip multidisciplinari. Aquest es compon de personal investigador mèdic i experimental que pertany a l’Hospital Universitari de Tarragona Joan XXIII i a l’Hospital Universitari Sant Joan de Reus: metges internistes, cirurgians, patòlegs, biòlegs moleculars i tècnics de laboratori.
GEMMAIR té una trajectòria de més de 25 anys d’experiència en l’estudi de malalties hepàtiques cròniques i de més de 15 anys en l’estudi de l’obesitat i les malalties associades. Tanmateix, GEMMAIR està acreditat com a grup consolidat per l’Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) des de l’any 2009 i és un grup de recerca reconegut per la Universitat Rovira i Virgili (URV).
GEMMAIR ha realitzar diverses col·laboracions en l’àmbit nacional i internacional; a més el grup té una gran vinculació amb l’àmbit acadèmic, donat que la major part dels membres del grup son professors de la URV. També s’hi han dut a terme un gran nombre de tesis doctorals i treballs de final de grau i de màster, pel que GEMMAIR, té experiència en la formació del personal investigador novell.

  • Estudi de citoquines i adipocitoquines en la fisiopatologia de l’obesitat, la síndrome metabòlica i la malaltia de fetge gras no alcohòlic (MFGNA).

  • Expressió gènica, factors transcripcionals i epigenètica en la MFGNA.

  • Estudi dels metabòlits derivats de la microbiota en la MFGNA.

  • Ciències òmiques (metabolòmica, miRNòmica i proteòmica) en el diagnòstic no invasiu de l’esteatohepatitis no alcohòlica.

  • Ciències òmiques (metabolòmica i proteòmica) en l’estudi de la placa arterial arterioscleròtica.

  • Biomarcadors pronòstics de la COVID-19 en pacients amb obesitat i/o síndrome metabòlica.

  • Malaltia tromboembòlica venosa.

  • WASTEwater as a source of knowledge on SARS-CoV-2 and other potentially pandemic VIRuses: a One Health approach (VIRWASTE). AGAUR. 01/05/2021-31/12/2023. 316.000€.

  • Biomarcadores de pronóstico circulantes y celulares para la progresión de COVID19 enpacientes con infección por SARS-CoV-2 utilizando ciencia multiómica. AGAUR. FRANCISCO VIDAL MARSAL. (FUNDACIÓ PRIVADA IISPV). 30/03/2020-31/12/2020.
    201.070,79 €.

  • PI16/00498, Papel de la disbiosis intestinal en la patogenia de la enfermedad del hígado graso no alcohólico a través de la regulación de la homeostasis lipídica hepática Instituto de Salud Carlos III. Maria Teresa Auguet Quintillà. URV. 01/01/2017-31/12/2019. 71.500€.

  • 2016PFR-URV-B2-72, Grup d’Estudi de Malalties Metabòliques associades a Insulin
    Resistència (GEMMAIR) Universitat Rovira i Virgili. Cristobal Manuel Richart Jurado.
    URV. 01/01/2017-30/06/2018. 6.572,17 €.

  • 2016PFR-URV-B2-72, Programa de suport als grups de recerca reconeguts. Grup d’Estudi
    de Malalties Metabòliques associades a Insulin Resistència (GEMMAIR) Universitat
    Rovira i Virgili. Cristobal Manuel Richart Jurado. URV. 01/01/2017- 31/12/2017.
    6.572,17 €.

  • 2015PFR-URV-B2-72, Grup d’Estudi de Malalties Metabòliques associades a Insulin
    Resistència (GEMMAIR) Universitat Rovira i Virgili. Cristobal Manuel Richart Jurado.URV.
    01/01/2015-31/12/2017. 6.839 €.

  • 2015PFR-URV-B2-72, Programa de suport als grups de recerca reconeguts. Grup d’Estudi
    de Malalties Metabòliques associades a Insulin Resistència (GEMMAIR) Universitat
    Rovira i Virgili. Cristobal Manuel Richart Jurado.URV. 01/01/2015- 31/12/2017. 6.839 €.

    Assajos clínics:

  • A Phase IIb/III Randomized, Double-blind,Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-Alcoholic
    Steatohepatitis with Fibrosis (D5671C00006). AstraZenecaAB. Desde 2022. IP: Dr. David Riesco

  • Phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of recombinant human plasma gelsolin (RHUPGSN) added to standard of care for treatment of subjects with severe covid-19 pneumonia.
    . Desde 2020. IP: Dra. T. Auguet

  • Safety and efficacy of favipipravir in COVID-19 patients with pneumonia. A randomized, double blind, placebo controlled study (FAVID01-20-SP).Ferrer Internacional, S.A. Desde 2020. IP: Dra. T. Auguet

  • Roso-Llorach, Albert; Serra-Picamal, Xavier; Cos, Francesc X; et al; Paredes, Roger. 2022.Evolving mortality and clinical outcomes of hospitalized subjects during successive COVID-19 waves in Catalonia, Spain. Global epidemiology. 4.
    https://doi.org/10.1016/j.gloepi.2022.100071
  • Auguet, Teresa (AC); López-Dupla, Miguel; Ramos, Jessica; et al; Richart, Cristóbal. 2022. Lipocalin, Resistin and Gut Microbiota-Derived Propionate Could Be Used to Predict
    Metabolic Bariatric Surgery Selected Outcomes. Processes. 10. https://doi.org/10.3390/pr10010143

  • Reverté, Laia; Yeregui, Elena; Olona, Montserrat; et al; Auguet, Teresa; Study Group, COVIDOMICS. 2022. Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. Clinical and Translational Medicine. 12-1, pp.e704-e704. https://doi.org/10.1002/ctm2.704

  • Perpiñan, Carles; Bertran, Laia; Terra, Ximena; et al; Auguet, Teresa; behalf of COVID-19 Study Group. 2022. Resistin and IL-15 as Predictors of Invasive Mechanical Ventilation in COVID-19 Pneumonia Irrespective of the Presence of Obesity and Metabolic Syndrome. Journal of Personalized Medicine. 12-3. https://doi.org/10.3390/jpm12030391

  • Bikdeli, Behnood; Jiménez, David; Demelo-Rodriguez, Pablo; et al; the RIETE Investigators, for. 2022. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry Viruses. 14-2. https://doi.org/10.3390/v14020178

  • Mostaza, Jose Maria; Suarez Carmen; et al; on behalf of the PERFILAR study
    investigators. Demographic, clinical, and functional determinants of antithrombotic
    treatment in patients with nonvalvular atrial fibrillation. BMC Cardiovascular Disorders.
    2021. 21-1.
  • Asano, Takaki; Boisson, Bertrand; et al; Casanova Jean-Laurent. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. SCIENCE IMMUNOLOGY. 2021. 6-62. https://doi.org/10.1126/sciimmunol.abl4348

  • Bertran L; Portillo-Carrasque M; Martinez S; et al; Auguet T. 2021. Expression of Jejunal Taste Receptors in Women with Morbid Obesity. NUTRIENTS. https://doi.org/10.3390/nu13072437

  • Villar, B; Bertran L; Aguilar C; et al; Auguet T. 2021. Circulating Levels of Pro-Neurotensin and Its Relationship with Nonalcoholic Steatohepatitis and Hepatic Lipid Metabolism Metabolites. https://doi.org/10.3390/metabo11060373

  • Bertran L; Portillo-Carrasquer M; Aguilar C; et al; Auguet T. 2021. Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22136895

  • Bertran L; Pastor A; Portillo-Carrasquer M; et al; Auguet T. 2021. The Potential Protective
    Role of RUNX1 in Nonalcoholic Fatty Liver Disease. International Journal of Molecular
    Sciences.
  • Perpiñan C; Bertran L; Terra X; et al; Auguet T. 2021. Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome. Journal of Personalized Medicine. https://doi.org/10.3390/ jpm11030227

  • J Trujillo-Santos; P Beroiz; et al. 2020. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism Thrombosis Research. 193, pp.160-165. https://doi.org/10.1016/j.thromres.2020.10.001

  • PR Sada; JJ López-Nuñez; A Samperiz; et al. 2020. Venous Thromboembolism in Patients
    with Autoimmune Disorders: Findings from the RIETE Registry Angiology. 71-2, pp.131-
    138.
  • Binetti J; Bertran L; Riesco D; et al; Auguet T. 2020. Deregulated Serotonin Pathway in
    Women with Morbid Obesity and NAFLD. LIFE.
  • Bastard, Paul; Rosen, Lyndsay B; et al; Casanova Jean-Laurent. Auto-antibodies against
    type I IFNs in patients with life-threatening COVID-19. SCIENCE. 2020. pp.423.
  • Zhang, Qian; Bastard, Paul; et al; Casanova Jean-Laurent. Inborn errors of type I IFN
    immunity in patients with life-threatening COVID-19. SCIENCE. 2020. pp.422.
  • Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020. Hepatocyte Notch Signaling Deregulation Related to Lipid Metabolism in Women with Obesity and Nonalcoholic Fatty Liver. Obesity. 28-8, pp.1487-1493. https://doi.org/10.1002/oby.22873

  • Alfredo Bardaji; Anna Carrasquer; Raul Sánchez-Giménez; et al; 2020. Implicaciones pronósticas del daño miocárdico en pacientes con y sin diagnóstico confirmado de COVID-19 atendidos en un hospital universitario. Rev Esp Cardiol. https://doi.org/10.1016/j.recesp.2020.08.009

  • Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020. Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences. 21-11. https://doi.org/10.3390/ijms21114189

  • Aragonès, G.; Colom Pellicer, M.; Aguilar, C.; et al; Auguet, T. 2019. Circulating
    microbiota-derived metabolites: a “liquid biopsy?. International journal of obesity.
  • Mastroiacovo D; Dentali F; di Micco P; et al. RIETE Investigators.2019. Rate and duration
    of hospitalisation for acute pulmonary embolism in the real-world clinical practice of
    different countries: analysis from the RIETE registry. 903624 – European Respiratory
    Journal. 53-2.
  • O Avnery; M Martin; A Bura-Riviere; et al. 2019. D-dimer levels and risk of recurrence
    following provoked venous thromboembolism: findings from the RIETE registry. J Intern
    Med.
  • PR Sada; JJ López-Nuñez; A Samperiz; et al. 2019. Venous Thromboembolism in Patients
    with Autoimmune Disorders: Findings from the RIETE Registry. Angyology. SAGE. pp.1-
    8.
  • Binetti J; Bertran L; Riesco D; et al; Auguet T. 2020. Deregulated Serotonin Pathway in
    Women with Morbid Obesity and NAFLD. LIFE.
  • Bastard, Paul; Rosen, Lyndsay B; et al; Casanova Jean-Laurent. Auto-antibodies against
    type I IFNs in patients with life-threatening COVID-19. SCIENCE. 2020. pp.423.
  • Zhang, Qian; Bastard, Paul; et al; Casanova Jean-Laurent. Inborn errors of type I IFN
    immunity in patients with life-threatening COVID-19. SCIENCE. 2020. pp.422.
  • Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020. Hepatocyte Notch Signaling Deregulation Related to Lipid Metabolism in Women with Obesity and Nonalcoholic Fatty Liver. Obesity. 28-8, pp.1487-1493. https://doi.org/10.1002/oby.22873

  • Alfredo Bardaji; Anna Carrasquer; Raul Sánchez-Giménez; et al; 2020. Implicaciones pronósticas del daño miocárdico en pacientes con y sin diagnóstico confirmado de COVID-19 atendidos en un hospital universitario. Rev Esp Cardiol. https://doi.org/10.1016/j.recesp.2020.08.009

  • Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020. Relationship
    between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid
    Obesity and Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences.
    21-11.
  • Aragonès, G.; Colom Pellicer, M.; Aguilar, C.; et al; Auguet, T. 2019. Circulating
    microbiota-derived metabolites: a “liquid biopsy?. International journal of obesity.
  • Mastroiacovo D; Dentali F; di Micco P; et al. RIETE Investigators.2019. Rate and duration
    of hospitalisation for acute pulmonary embolism in the real-world clinical practice of
    different countries: analysis from the RIETE registry. 903624 – European Respiratory
    Journal. 53-2.
  • O Avnery; M Martin; A Bura-Riviere; et al. 2019. D-dimer levels and risk of recurrence
    following provoked venous thromboembolism: findings from the RIETE registry. J Intern
    Med.
  • PR Sada; JJ López-Nuñez; A Samperiz; et al. 2019. Venous Thromboembolism in Patients
    with Autoimmune Disorders: Findings from the RIETE Registry. Angyology. SAGE. pp.1-
    8.
  • Gemma Aragonès; Sergio González-García; Carmen Aguilar; Cristóbal Richart; Teresa Auguet. 2019. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Research International. https://doi.org/10.1155/2019/8507583

  • Auguet T; Aragonès G; Berlanga A; et al; Richart C. 2018. Low circulating levels of neurotensin in women with non-alcoholic fatty liver disease associated to severe obesity. Obesity. 26-2, pp.274-278. https://doi.org/10.1002/oby.22058

  • Moustafa, Farès; Pesavento, Raffaele; di Micco, Pierpaolo; et al; RIETE Investigators, the.
    2018. Real-life Use of Anticoagulants in Venous Thromboembolism with a Focus on
    Patients with Exclusion Criteria for Direct Oral Anticoagulants Clinical Pharmacology &
    Therapeutics. 103-4, pp.684-691.
  • Kuperman A; López-Reyes R; Bosco LJ; et al; RIETE Investigators. 2018. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.910696 – Journal of Thrombosis and Thrombolysis. 45-3, pp.360-368. https://doi.org/10.1007/s11239-018-1610-9

  • Weinberg I; Giri J; Kolluri R; et al; RIETE Investigators. 2018. Characteristics, treatment
    patterns and outcomes of patients presenting with venous thromboembolic events
    after knee arthroscopy in the RIETE Registry.910696 Journal of Thrombosis and
    Thrombolysis. 46-4, pp.551-558.
  • Nieto JA; Vicente JA; Prieto LM; et al; RIETE Investigators. 2018. Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days 900566 – American Heart Journal. 206, pp.1-10. https://doi.org/10.1016/j.ahj.2018.08.014

  • Auguet T; Aragonès G; Colom M; Aguilar C; Martín-Paredero V; Canela N; Ruyra X;
    Richart C. 2018. Targeted metabolomic approach in men with carotid plaque. Plos One.
    13.
  • ara-Palomares, L.; Otero, R.; Jimenez, D.; et al; Mazzolai,L. 2017. Development of a Risk
    Prediction Score for Occult Cancer in Patients With VTE. CHEST. 151-3, pp.564.
  • Auguet T; Aragonès G; Berlanga A; et al; Richart C. 2017. Hepcidin in morbidly obese
    women with non-alcoholic fatty liver disease. PlosOne.

Membres De L’equip

  • Responsable de grup:

    • Teresa Auguet Quintillà
  • Investigadors clínics:

    • Marta París Sans
    • Fàtima Sabench Pereferrer
    • Margarida Vives Espelta
    • David Riesco Acevedo
    • José Antonio Porras Ledante
    • Salomé Martínez González
    • Daniel Del Castillo Déjardin
    • Jessica Binetti
    • Ajla Alibalic
  • Investigador Emèrit:

    • Cristóbal Manuel Richart Jurado
  • Investigadors post-doctorals:

    • Javier Ugarte Chicote
  • Investigadors pre-doctorals:

    • Laia Bertran Ramos
  • Tècnics de laboratori:

    • Carmen Aguilar Crespillo